North America Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ( Voriconazole, Liposomal, Amphotericin B, Systemic Oral Azoles, Topical, Antifungal Agents, and Others ); Application ( Chronic, Pulmonary Aspergillosis (CPA), Allergic, Bronchopulmonary Aspergillosis (ABPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, and Others ); and Country

Code: TIPRE00020066 | Pages: 127 | Industry: Pharmaceuticals | Date: Mar 2021 | Type: Regional

Market Introduction

Fungal systemic infections are common in patients with weakened immune system, including immunosuppression and acquired immunodeficiency syndrome (AIDS) patients. Systemic signs consolidate apnea, guaiac-positive stools, abdominal distension, hyperglycemia, leukemoid reaction, hypotension, and others. The treatment of systemic candidiasis and aspergillos need parenteral antifungal therapy and this condition is associated with high mortality rate. Furthermore, this infection may result in permanent neurodevelopmental deficits in long-term survivors.


Get more information on this report :



Market Overview and Dynamics

The North America Systemic Aspergillosis and Systemic Candidasis market is projected to reach US$ 3,352.62 million by 2027 from US$ 2,423.82 million in 2019; it is estimated to grow with a CAGR of 4.2% from 2020 to 2027. The growth of the North America systemic aspergillosis and systemic candidasis market is attributed to the rise in prevalence of fungal diseases, rising hospital acquired fungal infection. However, increasing resistance to antifungal drugs, side effects of antifungal drugs limits the growth of market in this region. Countries in North America are expecting to witness huge challenge due to growing COVID-19. Due to outbreak of disease, healthcare industries has been affected badly. Due to growing COVID-19 cases, many business related activities such as product launches and product promotion conferences has been postponed, leading to restraining the growth of the market.

Key Market Segments

Based on type, the North America systemic aspergillosis and systemic candidasis market is segmented into voriconazole, liposomal, amphotericin b, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment held a larger share of the market. And is expected to grow at a faster rate during the forecast period.

Major Sources and Companies Listed

A few major primary and secondary sources referred to while preparing the North America systemic aspergillosis and systemic candidasis Market report are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.

Novartis AG, Sanofi, Pfizer Inc., Merck & Co., Inc., Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plc., Abbott, Cipla Inc., Enzon Pharmaceuticals, Inc,.

 

Reasons to buy the report

  • To understand the North America systemic aspergillosis and systemic candidasis market landscape and identify market segments that are most likely to guarantee a strong return
  • To stay ahead in comprehending the ever-changing competitive landscape of the North America systemic aspergillosis and systemic candidasis market
  • To efficiently plan M&A and partnership deals in the North America systemic aspergillosis and systemic candidasis market by identifying market segments with the most promising probable sales
  • To help take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segments in the North America systemic aspergillosis and systemic candidasis market
  • To obtain market revenue forecast from 2019 to 2027 in various segments of the North America systemic aspergillosis and systemic candidasis market

NORTH AMRICA SYSTEMIC ASPERGILLOSIS AND SYSTEMIC CANDIDASIS MARKET SEGMENTATION

By Type

  • Systemic Oral Azoles
  • Voriconazole
  • Liposomal Amphotericin B
  • Topical Antifungal Agents
  • Others

By Application

  • Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Chronic Pulmonary Aspergillosis (CPA)
  • Gastrointestinal Candidiasis
  • Genitourinary Tract Candidiasis
  • Others

By Country

  • US
  • Canada
  • Mexico

 

Company Profiles

  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • Cipla Inc.
  • ENZON PHARMACEUTICALS, INC.
 

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Systemic Aspergillosis and Systemic Candidasis Market – By Type

1.3.2        North America Systemic Aspergillosis and Systemic Candidasis Market – By Application

1.3.3        North America Systemic Aspergillosis and Systemic Candidasis Market – By Country

2.           Systemic Aspergillosis And Systemic Candidasis Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America Systemic Aspergillosis and Systemic Candidasis Market– Market Landscape

4.1         Overview

4.2         PEST Analysis

4.3         Expert Opinions

4.4         Clinical Trials Phases of Products Offered by Companies

4.5         Candida Specific Products

5.           Systemic Aspergillosis and Systemic Candidasis Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rise in Prevalence of Fungal Diseases

5.1.2        Rising Hospital Acquired Fungal Infection

5.2         Market Restraints

5.2.1        Increasing Resistance to Antifungal Drugs

5.2.2        Side Effects of Antifungal Drugs

5.3         Market Opportunities

5.3.1        Increase in R&D Activities and Pipeline of New Drug

5.4         Future Trends

5.4.1        Consolidation of Market

5.5         Impact Analysis

6.           Systemic Aspergillosis and Systemic Candidasis Market Analysis– by Type

6.1         Overview

6.2         North America Systemic Aspergillosis and Systemic Candidasis Market, by Type, 2019 and 2027 (%)

6.3         Voriconazole

6.3.1        Overview

6.3.2        North America Voriconazole Market Revenue and Forecasts to 2027 (US$ Mn)

6.4         Liposomal Amphotericin B

6.4.1        Overview

6.4.2        North America Liposomal Amphotericin B Market Revenue and Forecasts to 2027 (US$ Mn)

6.5         Systemic Oral Azoles

6.5.1        Overview

6.5.2        North America Systemic Oral Azoles Market Revenue and Forecasts to 2027 (US$ Mn)

6.6         Topical Antifungal Agents

6.6.1        Overview

6.6.2        North America Topical Antifungal Agents Market Revenue and Forecasts to 2027 (US$ Mn)

6.7         Others

6.7.1        Overview

6.7.2        North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

7.           Systemic Aspergillosis and Systemic Candidasis Market Analysis– by Application

7.1         Overview

7.2         North America Systemic Aspergillosis and Systemic Candidasis Market, by Type, 2019 and 2027 (%)

7.3         Chronic Pulmonary Aspergillosis (CPA)

7.3.1        Overview

7.3.2        North America Chronic pulmonary aspergillosis (CPA) Market Revenue and Forecasts to 2027 (US$ Mn)

7.4         Allergic Bronchopulmonary Aspergillosis (ABPA)

7.4.1        Overview

7.4.2        North America Allergic bronchopulmonary aspergillosis (ABPA) Market Revenue and Forecasts to 2027 (US$ Mn)

7.5         Gastrointestinal Candidiasis

7.5.1        Overview

7.5.2        North America Gastrointestinal Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

7.6         Genitourinary Tract Candidiasis

7.6.1        Overview

7.6.2        North America Genitourinary Tract Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

8.           Systemic Aspergillosis and Systemic Candidiasis Market – Regional Analysis

8.1         Overview

8.1.1        North America: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.2        North America Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

8.1.3        North America Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

8.1.4        North America Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

8.1.5        US: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.1          US: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.2          US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

8.1.5.3          US: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

8.1.6        Canada: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.1          Canada: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.2          Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

8.1.6.3          Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

8.1.7        Mexico: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.1          Mexico: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.2          Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Type, 2018–2027 (USD Million)

8.1.7.3          Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Application, 2018–2027 (USD Million)

9.           Impact of COVID-19 Pandemic on North America Systemic Aspergillosis and Systemic Candidiasis Market

9.1         Impact Assessment of COVID-19 Pandemic

10.        COMPANY PROFILES

10.1      Novartis AG

10.1.1     Key Facts

10.1.2     Business Description

10.1.3     Products and Services

10.1.4     Financial Overview

10.1.5     SWOT Analysis

10.1.6     Key Developments

10.2      Sanofi

10.2.1     Key Facts

10.2.2     Business Description

10.2.3     Products and Services

10.2.4     Financial Overview

10.2.5     SWOT Analysis

10.2.6     Key Developments

10.3      Pfizer Inc.

10.3.1     Key Facts

10.3.2     Business Description

10.3.3     Products and Services

10.3.4     Financial Overview

10.3.5     SWOT Analysis

10.3.6     Key Developments

10.4      Merck & Co., Inc.

10.4.1     Key Facts

10.4.2     Business Description

10.4.3     Products and Services

10.4.4     Financial Overview

10.4.5     SWOT Analysis

10.4.6     Key Developments

10.5      Bayer AG

10.5.1     Key Facts

10.5.2     Business Description

10.5.3     Products and Services

10.5.4     Financial Overview

10.5.5     SWOT Analysis

10.5.6     Key Developments2

10.6      Astellas Pharma Inc.

10.6.1     Key Facts

10.6.2     Business Description

10.6.3     Products and Services

10.6.4     Financial Overview

10.6.5     SWOT Analysis

10.6.6     Key Developments6

10.7      GlaxoSmithKline plc.

10.7.1     Key Facts

10.7.2     Business Description

10.7.3     Products and Services

10.7.4     Financial Overview

10.7.5     SWOT Analysis

10.7.6     Key Developments

10.8      Abbott

10.8.1     Key Facts

10.8.2     Business Description

10.8.3     Products and Services

10.8.4     Financial Overview

10.8.5     SWOT Analysis6

10.8.6     Key Developments

10.9      Cipla Inc.

10.9.1     Key Facts

10.9.2     Business Description

10.9.3     Products and Services

10.9.4     Financial Overview

10.9.5     Key Developments

10.10   ENZON PHARMACEUTICALS, INC

10.10.1  Key Facts

10.10.2  Business Description

10.10.3  Products and Services

10.10.4  Financial Overview

10.10.5  SWOT Analysis

10.10.6  Key Developments

11.        Appendix4

11.1      About the Insight Partners

11.2      Glossary of Terms

LIST OF TABLES

Table 1.             Clinical Trials Phases of Products Offered by Companies

Table 2.             Candida Specific Products

Table 3.             Clinical cases of Candida auris reported by U.S. states, as of November 30, 2020

Table 4.             North America Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 5.             North America Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 6.             US: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 7.             US: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027

Table 8.             Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 9.             Canada: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 10.          Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 11.          Mexico: Systemic Aspergillosis and Systemic Candidiasis Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 12.          Glossary of Terms, Systemic Aspergillosis And Systemic Candidiasis Market4

 

LIST OF FIGURES

Figure 1.           Systemic Aspergillosis And Systemic Candidasis Market Segmentation

Figure 2.           Systemic Aspergillosis And Systemic Candidasis Market, By Region

Figure 3.           North America Systemic Aspergillosis And Systemic Candidasis Market Overview

Figure 4.           Systemic Oral Azoles Segment Held Largest Share of Type Segment In Systemic Aspergillosis And Systemic Candidasis Market

Figure 5.           Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period

Figure 6.           PEST Analysis

Figure 7.           Systemic Aspergillosis and Systemic Candidasis Market Impact Analysis of Drivers and Restraint

Figure 8.           North America Systemic Aspergillosis and Systemic Candidasis Market breakdown, by Type, 2019 and 2027 (%)

Figure 9.           North America Voriconazole Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 10.        North America Liposomal Amphotericin B Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        North America Systemic Oral Azoles Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        North America Topical Antifungal Agents Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        North America others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        North America Systemic Aspergillosis and Systemic Candidasis Market breakdown, by Type, 2019 and 2027 (%)

Figure 15.        North America Chronic pulmonary aspergillosis (CPA) Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 16.        North America Allergic bronchopulmonary aspergillosis (ABPA)Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        North America Gastrointestinal Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        North America Genitourinary Tract Candidiasis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        North America others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Key Country – Revenue (2019) (USD Million)

Figure 21.        North America: Systemic Aspergillosis and Systemic Candidiasis Market Revenue and Forecast to 2027 (USD Million)

Figure 22.        North America: Systemic Aspergillosis and Systemic Candidiasis Market, by Country, 2019 & 2027 (%)

Figure 23.        US: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

Figure 24.        Canada: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

Figure 25.        Mexico: Systemic Aspergillosis and Systemic Candidiasis Market – Revenue and Forecast to 2027 (USD Million)

Figure 26.        Impact of COVID-19 Pandemic in North American Country Markets

  1. Novartis AG
  2. Sanofi
  3. Pfizer Inc.
  4. Merck & Co., Inc.
  5. Bayer AG
  6. Astellas Pharma Inc.
  7. GlaxoSmithKline plc.
  8. Abbott
  9. Cipla Inc.
  10. Enzon Pharmaceuticals, Inc.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000